QMengColdJoke : still a fraud after 40 to 1 reverse split.

TechTrek Invest OP QMengColdJoke : That's a very emotional response. Where is the evidence? Have you notified the SEC of your findings?
What's the fraud?
Share price falling isn't fraudulent.
COVID profits fell considerably - again losing revenue streams.is not fraudulent.
Core buisiness is growing.
Good AI development.
Reducing cost.
Ginkgo has good long term.potential.

101674396 QMengColdJoke : Yes.

QMengColdJoke TechTrek Invest OP : i doubled my position at 7, not yet sold. Generally speaking, people like IPO between 10 to 50 a share. Just mental things, a meal for a share, a few grands for a lot. Reverse split might be needed when price is below 1. Just say we are at 50 cents. Therefore reverse split expecting recovery will do 3 to 5. Moderate ratio is 6 to 10. negative if you do 20. But 40 is really bad. Company with regular cash flow can get loans. But for biotech, mostly only financing is through equity offering. The condition is at least company can maintain stock price, so institute can dump to retail if things go bad. That just means CFO is a rookie.
Che Austin sells like everyday for merely 50k where his salary is like 200k a year. How will people thinking? That means DNA is poor in internal control. IR and company consular do not review SEC filing or waste 30 minutes everyday to review Che’a selling for a thousand?

QMengColdJoke TechTrek Invest OP : Be serious, current revenue comes from collaboration R&D contracts. But shares of their clients are all weak in 2024, budget for 2025 must be tight. So don’t expect good new contracts. They need to have real product to prove themselves. A commercial product is only way I am looking for. The reality is there are so many fraud biotech, who just think shareholders’ money are like funding in University, free money. Especially new biotech companies founded after 2020 (not Ginkgo) They don’t even want to move to clinical

TechTrek Invest : I'm buying little and often.